Home > Journals > Minerva Cardioangiologica > Past Issues > Articles online first > Minerva Cardioangiologica 2020 Apr 23

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Minerva Cardioangiologica 2020 Apr 23

DOI: 10.23736/S0026-4725.20.05184-1

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

The coronary resorbable magnesium scaffold Magmaris: what we've learnt (so far...)

Johan BENNETT 1, 2 , Keir McCUTCHEON 1

1 Department of Cardiovascular Medicine, University Hospitals Leuven, Leuven, Belgium; 2 Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium


PDF


Bioresorbable scaffold (BRS) technology provides transient vessel support with drug-delivery capability without the long-term limitations of the permanent metallic drug-eluting stents (DES). Numerous scaffolds have been developed and investigated by device manufacturers, many of which, due to device deficiencies, have fallen by the way side. This short review will focus on the resorbable magnesium scaffold “Magmaris”, the only metallic bioresorbable scaffold currently available, providing an evaluation of the most up to date clinical data whilst also briefly highlighting learning points regarding the ideal patient and lesion choice and optimal implantation technique.


KEY WORDS: Magmaris; Coronary scaffold; Percutaneous coronary intervention; Resorbtion; Magnesium

top of page